Compare DBVT & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBVT | BVS |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | France | United States |
| Employees | 90 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.8M | 783.2M |
| IPO Year | 2014 | 2016 |
| Metric | DBVT | BVS |
|---|---|---|
| Price | $13.68 | $11.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $32.04 | $14.00 |
| AVG Volume (30 Days) | 275.2K | ★ 706.8K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.26 | ★ 163.46 |
| EPS | N/A | ★ 0.04 |
| Revenue | $5,636,000.00 | ★ $568,087,000.00 |
| Revenue This Year | $35.04 | $7.52 |
| Revenue Next Year | $2,360.78 | $7.06 |
| P/E Ratio | ★ N/A | $287.00 |
| Revenue Growth | ★ 35.77 | N/A |
| 52 Week Low | $8.51 | $5.81 |
| 52 Week High | $26.19 | $12.53 |
| Indicator | DBVT | BVS |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 58.18 |
| Support Level | $12.63 | $8.04 |
| Resistance Level | $14.68 | $12.53 |
| Average True Range (ATR) | 0.87 | 0.54 |
| MACD | -0.17 | -0.07 |
| Stochastic Oscillator | 11.88 | 41.30 |
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.